Natera, Inc. , a leader in personalized genetic testing and diagnostics, announced the company, along with its collaborators, will present new data on Natera’s personalized, tumor-informed molecular residual disease (MRD) test, Signatera, at the American Society of Clinical Oncology’s 2022 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 20 – 22, 2022.
Also Read: Pathogenomix granted FDA Breakthrough Device Designation
Natera has two oral presentations and four collaborative poster presentations highlighting clinical findings on the performance of Signatera across colorectal (CRC), pancreatic and anal cancers. The oral presentations include an interim analysis from the GALAXY cohort of the CIRCULATE-Japan trial, based on 12-month outcomes from more than 1,000 patients, demonstrating how MRD testing can help predict treatment benefit for CRC patients post-surgery, regardless of stage. A second oral presentation addresses results from the first major study on the utility of MRD testing for patients with pancreatic cancer, compared to the standard of care biomarker CA19-9.
“The predictive data coming out of CIRCULATE-Japan is exceptional, and we think it has the potential to transform clinical practice in CRC,” said Solomon Moshkevich, general manager of oncology at Natera. “We also look forward to presenting high-impact data from our pancreatic and other GI studies, further expanding the pan-cancer utility of Signatera’s personalized and tumor-informed method.”
Natera and its collaborators will present the following studies:
Oral Abstract Session C: Cancers of the Colon, Rectum and Anus |
Presenter: Masahito Kotaka, M.D., Ph.D. | Jan. 22, 11:00 AM – 12:30 PM PST
Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan
Oral Abstract Presentation: Emerging Roles of ctDNA on the Horizon of GI Cancers |
Presenter: Gregory Botta, M.D., Ph.D. | Jan. 20, 3:30 PM – 5:00 PM PST
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma
Poster Session C: Cancers of the Colon, Rectum, and Anus |
Presenter: Georges Azzi, M.D. | Jan. 22, 6:30 AM – 7:55 AM PST
Circulating tumor DNA-based molecular residual disease detection and recurrence monitoring in patients with advanced or metastatic anal squamous cell carcinoma
Poster Session C: Cancers of the Colon, Rectum, and Anus |
Presenter: RuoBing Xue, M.D. | Jan. 22, 6:30 AM – 7:55 AM PST
Prospective study of the correlation of ctDNA with pathologic complete remission (pCR) and other efficacy outcomes in rectal cancer patients undergoing neoadjuvant chemotherapy and radiation
Poster Session C: Cancers of the Colon, Rectum, and Anus |
Presenter: Sherise Rogers, M.D., M.P.H. | Jan. 22, 6:30 AM – 7:55 AM PST
A phase II randomized therapeutic optimization trial for subjects with refractory metastatic colorectal cancer using circulating tumor DNA (ctDNA): Rapid 1 trial
Poster Session C: Cancers of the Colon, Rectum, and Anus |
Presenter: Marwan Fakih, M.D. | Jan. 22, 6:30 AM – 7:55 AM PST
Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients (pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC)